Skip to content
Screener

LivaNova LIVN Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$362.3MBeat by $16.2M
EPS$0.98Beat by $0.13
Revenue estimate$346.1M
EPS estimate$0.85

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$381.1M
EPS estimate$1.04

Financials

Q1 2026

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$3.48B+62.8%
Enterprise value$3.28B+58.0%
P/S2.4×+0.8×

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Segments

By segment

See full
Cardiopulmonary$208.7M+18.3%
Neuromodulation$151.8M+9.3%

By geography

See full
Rest of World$101.9M+15.8%
Europe$75.7M+26.7%

FAQ

When did LivaNova report Q1 2026 earnings?
LivaNova (LIVN) reported Q1 2026 earnings on May 6, 2026 before market open.
What were LivaNova's Q1 2026 revenue and EPS?
LivaNova reported revenue of $362.3M and eps of $0.98 for Q1 2026.
Did LivaNova beat estimates in Q1 2026?
Revenue beat the consensus estimate of $346.1M by $16.2M. EPS beat the consensus estimate of $0.85 by $0.13.
How did LivaNova's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.3% from $316.9M a year earlier and eps grew 11.4% from $0.88.
Where can I find LivaNova's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001639691-26-000031) and the 10-Q periodic report (0001639691-26-000035) directly on SEC EDGAR. The filing index links above go to sec.gov.